Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
PBYI Institutional Ownership - Puma Biotechnology Inc Stock
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS | Business Wire
Puma Biotechnology shares rocket after biopharma zips past Street's 4Q estimate
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology out-licenses Nerlynx in Canada
Puma Biotechnology
Puma catches fifth approval, hunts new indication for Nerlynx
Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe - Pharmaceutical Business review
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference | Business Wire
Puma Biotechnology, Inc. 2020 Current Report 8-K
Former Puma Biotechnology exec is accused of making $1.2 million from insider trading - Los Angeles Times
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
puma pharmaceuticals stock price Off 54% - canerofset.com
ICOMPRE 2 DE CADA CAJA puma biotechnology inc Y OBTENGA UN 70% DE DESCUENTO!
In the wake of Puma Biotechnology, Inc.'s (NASDAQ:PBYI) latest US$17m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St News
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotech's Neratinib Fails To Extend Overall Survival In Brain Cancer Trial
Puma Pharma (@PumaPharma) / Twitter
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology Surging
Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib - Pharmaceutical Business review
